



Akebia Therapeutics
Investor Relations Department
245 First Street
Suite 1100
Cambridge, MA 02142
United States


Visit IR website [↗](#)
Sign-up for email alerts [↗](#)

NASDAQ: AKBA

Last Trade:	16.35
Trade Time:	4:15 PM ET Jun 23, 2017
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	7.00 - 16.54
Volume	N/A

Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Stock Performance



Press Releases [\[View all \]](#)

Jun 20, 2017

[Akebia Therapeutics to Host Analyst and Investor Day on June 27, 2017](#)

Jun 5, 2017

[Akebia Prevails in Two Additional European Patent Disputes](#)

May 25, 2017

[Akebia Therapeutics Names Rita Jain, M.D. as Chief Medical Officer](#)

May 24, 2017

[Akebia Initiates Phase 2 FO2RWARD Study of Vadadustat in Dialysis Patients with Anemia Related to Chronic Kidney Disease Hyporesponsive to Treatment with Erythropoiesis-Stimulating Agents](#)

May 15, 2017

[Akebia and Vifor Pharma Announce Exclusive License Agreement to Provide Vadadustat to Fresenius Medical Care in the U.S. Upon FDA Approval](#)

Upcoming Events [\[View all \]](#)

Jun 27, 2017 8:00 AM ET
[Akebia Investor Day 2017](#)

Financials [\[View all \]](#)

Mar 6, 2017

[Annual Report \(10-K\)](#)

May 1, 2017

[Proxy Statement \(DEF 14A\)](#)

May 9, 2017

[Quarterly Report \(10-Q\)](#)

Nov 9, 2016

[Quarterly Report \(10-Q\)](#)

Aug 8, 2016

[Quarterly Report \(10-Q\)](#)